Jeffrey R. Andolina, M.D., M.S.Email Jeffrey
The treatment and comprehensive care for children with leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), as well as the care for children with other cancers and blood diseases.
Andrew Evans, M.D., Ph.D.Email Andrew
Pathology & Laboratory Medicine
My current research focuses on the molecular, genetic, and immunologic mechanisms that underlie leukemia and lymphoma development. Specifically, I’m studying which bone marrow stromal interactions influence the development and persistence of these diseases. Other interests include the role of chronic viruses in lymphoma development, and the genetic characteristics that influence diagnosis and treatment of pre-myeloid leukemias or myelodysplastic syndromes.
Benjamin Frisch, Ph.D.Email Benjamin
My research concentrates on the reciprocal interactions between the bone marrow microenvironment and hematopoietic stem cells (HSCs), under both normal and leukemic conditions. My research efforts are largely translational in focus with the ultimate goal of therapeutically targeting the bone marrow microenvironment for the treatment of hematologic malignancies.
Chunkit Fung, M.D.Email Chunkit
Cancer control, particularly in the development, implementation, and dissemination of mHealth behavioral interventions to prevent and manage treatment- and cancer-related toxicities in cancer survivors, with a specific focus in cardiovascular complications from cancer treatment
Jean V. Joseph, M.D.Email Jean
Laparoscopic/minimally invasive urology (prostatectomy, nephrectomy), reconstructive urology, hematuria, genitourinary cancers, kidney stones, benign prostatic hypertrophy (BPH), urethral strictures, vasectomy, vasectomy reversal
Lynne Maquat, Ph.D.Email Lynne
Biochemistry & Biophysics
RNA metabolism in human cells (nonsense-mediated mRNA decay/mRNA surveillance); influence of pre-mRNA splicing on mRNA translation; Staufen-mediated mRNA decay and Staufen-regulated RNA metabolism; post-transcriptional gene control via lncRNAs and SINEs; miRNA metabolism; Fragile X Mental Retardation Syndrome/Autism; therapeutics of nonsense diseases.